VCAM1 and neoplasm: MP6-XT22 was shown to decrease co-expression of CD31 and VCAM1 in the tumor areas compared to those in untreated vehicle control (score 3.2 vs 1.8, p = 0.03, right panels in Fig. 5e, f) and increase survival (log-rank test, p = 0.0008, Fig. 5h).